Global Myasthenia Gravis Treatment Market Size To Exceed USD 3.42 Billion by 2035 | CAGR 7.72%
Category: HealthcareGlobal Myasthenia Gravis Treatment Market Size To Exceed USD 3.42 Billion by 2035
According to a Research Report Published By Spherical Insights & Consulting, The Global Myasthenia Gravis Treatment Market Size is Expected to Grow from USD 1.51 Billion in 2024 to USD 3.42 Billion by 2035, at a CAGR of 7.72% during the Forecast Period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 245 pages with 122 Market data tables and figures & charts from the report on the “Global Myasthenia Gravis Treatment Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, IVIg, and Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.” Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/myasthenia-gravis-treatment-market
The Myasthenia Gravis Treatment Market Size is the international industry focused on developing and distributing treatment solutions for myasthenia gravis (MG), a chronic autoimmune neuromuscular disease that causes muscle weakness. The myasthenia gravis treatment market focus on wide range of therapeutic approaches, such as immunosuppressants, corticosteroids, cholinesterase inhibitors, monoclonal antibodies, plasma exchange, and surgery. The market is expanding as a result of government initiatives to improve healthcare facilities and increase awareness of myasthenia gravis. The primary factors driving the myasthenia gravis treatment market's growth are the increasing prevalence of myasthenia gravis, awareness of early diagnosis, and adoption of cutting-edge treatment alternatives. The prevalence of autoimmune diseases, the availability of improved healthcare infrastructure, the increase in unmet healthcare needs, and the spike in demand for novel myasthenia gravis treatment drugs are all expected to contribute to the growth of the myasthenia gravis treatment market in emerging markets. However, Immunosuppressant side effects, high treatment costs, poor reimbursement practices, low knowledge, and regulatory obstacles restrict market expansion.
The IVIg segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the drug class, the myasthenia gravis treatment market is divided into cholinesterase inhibitors, corticosteroids, immunosuppressants, IVIg, and monoclonal antibodies. Among these, the IVIg segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Higher prices and more sophisticated research and development by the major companies in the launch of new IVIg medications for the illness are also expected to support the segment's expansion.
The hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the distribution channel, the myasthenia gravis treatment market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The increased number of doctor visits and hospitalizations is the reason for the hospital pharmacies.
North America is expected to hold the majority share of the global myasthenia gravis treatment market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global myasthenia gravis treatment market during the forecast period. The widespread use of immunotherapies and monoclonal antibodies, rising healthcare costs, well-established R&D centers, and advantageous reimbursement situations are all factors contributing to North America's achievement. The factors driving the market's expansion during the forecast period are the region's growing elderly population and the disease's increasing prevalence.
Asia Pacific is anticipated to grow at the fastest pace in the global myasthenia gravis treatment market during the forecast period. The market is expanding as a result of improvements in diagnostic methods that enable more precise and prompt diagnosis of myasthenia gravis.
Europe is predicted to hold a significant share of the myasthenia gravis treatment market throughout the estimated period. The major actors are also working harder to create new treatments for the ailment as a result of the condition's increasing diagnosis and prevalence in the area.
Major vendors in the global myasthenia gravis treatment market are AbbVie Inc., Grifols SA, Shire plc, Pfizer, Inc., Novartis, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Alexion Pharmaceutical Inc., Bausch Health Companies Inc., Avadel Pharmaceuticals, Plc, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In August 2023, Astrazeneca stated that their drug Soliris (eculizumab) has received approval in Japan to treat children patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG).
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the myasthenia gravis treatment market based on the below-mentioned segments:
Global Myasthenia Gravis Treatment Market, By Drug Class
- Cholinesterase Inhibitors
- Corticosteroids
- Immunosuppressants
- IVIg
- Monoclonal Antibodies
Global Myasthenia Gravis Treatment Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Myasthenia Gravis Treatment Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?